

emyria

ASX : EMD

Delivering the new paradigm in mental health care

Techknow Presentation

July 2026



Disclaimer

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.

Who are we?

Emyria is addressing a significant and escalating gap in the mental healthcare market



Emyria is building a national network of clinics specialising in delivery of Psychedelic Assisted Therapy for PTSD and Treatment Resistant Depression.



Worldwide first mover advantage


A Regulated Access Pathway For Psychedelics to Treat our Most Serious and Urgent Mental Health Conditions



Australia


is the FIRST jurisdiction in the world to reschedule two promising treatments¹

MDMA-assisted therapy



For PTSD

Psilocybin-assisted therapy



For Depression


This regulation change has created a Significant Market Opportunity.

SOURCES

1 <https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorized-psychiatrists>

Patient journey | Treatment model + bed capacity

Medication, ~90 hours of Supervised Intensive Psychotherapy, Follow-Up



Significant Total Addressable Market
~1,100,000 adults in Australia have major depression (~4%)¹
~1,500,000 adults in Australia have PTSD (~7%)¹

Each dosing day ~\$10,000 revenue
PTSD Total treatment / patient ~\$33,000
Treatment Resistant Depression / patient ~\$22,000

SOURCES:
1).<https://www.abs.gov.au/statistics/health/mental-health/national-study-mental-health-and-wellbeing/latest-release#key-statistics>

BED CAPACITY		
Clinic	Beds	Dosing days / week
Perth (x2)	8	40
Brisbane	3	15
Melbourne	3	15
Sydney	4	20*
=	18	90


*When operational

Emyria's PTSD program is delivering durable and lasting results

Durable symptom and quality of life improvement, beyond 12 months



Average PCL-5¹ Scores by Visit (up to 12 months follow-up)



~67% of patients no longer meet criteria for PTSD diagnosis

~76% of patients have a clinically significant improvement

SOURCES:
1. The **PCL-5** is a self-administered, 20-item self-report tool used to measure PTSD symptoms according to diagnostic DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition).


Emyria's Treatment Resistant Depression program early outcomes¹

First Cohort of 10 patients - Clinically Significant Improvement



Depression symptoms improved in our first cohort

n = 10 patients



Lower is better. n = 10 patients in the first cohort with follow-up data. Early and exploratory data; not proof of effectiveness. QIDS-SR16 measures depression symptom severity; lower scores mean fewer symptoms.

Clinically significant reductions in:

- Depression Symptoms
- Trauma Symptoms

Improvements in:

- Quality of Life
- Daily functioning

All changes statistically significant¹

SOURCES:

¹ Refer ASX announcement 24 June 2026

Major Funders are spending Hundreds of Millions each year on mental health



Private Health Insurers



\$2B

spent by Medibank on mental health hospitalisations in last 10 years,

\$219M/yr

in 2024 alone. ¹

Only 26% of insured adults

Department of Veterans' Affairs



The Government spends

\$300M/yr on veteran mental health each year. ²

Almost **three in four** (veterans) are estimated to have met criteria for a mental disorder at some stage in their lifetime. ³

Other Insurers



Life insurers ... paid out more than

\$2.2B in 2024

for retail mental health claims in 2024 ⁴

SOURCES:


1. <https://www.heraldsun.com.au/health/mental-health/alarming-research-shows-extent-of-mental-health-crisis-in-australia/news-story/66f6937a316f9dd54673c5a6f692b232>

2. https://www.dva.gov.au/sites/default/files/twrp_mhpr.pdf

3. <https://www.dva.gov.au/news/latest-stories/report-hospitalisations-suicidality-and-self-harm-released#:~:text=The%20Australian%20Government%20is%20committed,%E2%80%93%20Veterans%20&%20Families%20Counselling%20Service.>

4. <https://www.abc.net.au/news/2025-07-16/spike-in-mental-health-illness-claims-super-funds-delay-payouts/105531022>

MDMA-AT cost¹ vs standard of care for PTSD^{2, 3}



Sources:
1. Costs are estimated based on estimates of direct clinician time required to delivery program
2. Standard of care costs based on conversations with clinical specialists. WA East Metropolitan Health Service reported Specialised Mental Health Care Days average cost of \$2,156 per day in FY 2022 / 2023 (<https://annualreport.emhs.health.wa.gov.au/key-performance-indicators/browse-kpis/average-cost-per-bed-day-in-specialised-mental-health-inpatient-services/>)
3. Marseille E, et al. The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. PLoS One. 2020 Oct 14;15(10):e0239997. doi: 10.1371/journal.pone.0239997. PMID: 33052965; PMCID: PMC7556534.

Third party funding

Reimbursement has commenced for Psychedelic Assisted Therapy



Key funding bodies^{1,2}

medibank



Australian Government
Department of Veterans' Affairs

**WORKER'S
COMPENSATION**



**Other ad
hoc approvals**

Case by case
approvals have
occurred from other
funding bodies



Work in progress

We continue to
engage other private
health insurers,
workers
compensation
insurers and other
funding bodies


SOURCES:

1. See ASX announcement 18 June 2025

2. See ASX announcement 20 November 2025

Typical timeline to projected clinic profitability


Current Clinic Status



Perth Clinic	+
Brisbane	+
Mornington (VIC)	+
Sydney	+

SOURCES:
1. See ASX announcement 11 June 2026


Maturing clinic I Perth Clinic dosing days May 2025 to June 2026



* Monthly stand alone clinic breakeven.

SOURCES:
1. See ASX announcement 11 June 2026

Highly defensible healthcare business



Scalable contractor workforce

Capital light and flexible workforce to support growing clinic utilisation



	Therapists trained and contracted	Authorised Prescribers (AP)
Perth (x2 Clinic)	~35	8 approved 1 in application process
Brisbane	~25	5 approved
Melbourne	~25	1 approved 3 in application process
Sydney	~20	4 in application process

Emyria provides a specialised training and regulatory pathway for psychiatrists and therapists

Significant momentum in psychedelic drug treatments

Recent macro catalysts provide significant tailwinds for Emyria



Big Pharma And Psychedelic Medicine—Eli Lilly’s \$3.8 Billion Bet **Forbes**

Emyria moves on clinical drugs play
BUSINESSNEWS

Trump announces reforms to accelerate access to psychedelic drug treatments

President signed executive order directing FDA to expedite review of psychedelic drugs including ibogaine



AMERICAN PSYCHOLOGICAL ASSOCIATION

FEATURE

The emergence of psychedelics as medicine

A look at the potential of MDMA, ketamine, and psilocybin to help people with treatment-resistant mental health conditions

Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins **MarketBeat**

Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists



Australian Government

Department of Health, Disability and Ageing
Therapeutic Goods Administration


Emyria is well positioned to leverage this momentum, writing the playbook for psychedelic drug delivery

SOURCES

1. <https://psychedelics.berkeley.edu/clinical-trials-map>

Potential future treatable conditions

Significant global research in psychedelic drugs



New Treatable
Conditions
Increase Total
Addressable
Market

SOURCES
1. <https://psychedelics.berkeley.edu/clinical-trials-map>

Emyria has established versatile delivery infrastructure

Infrastructure able to support growing, global research effort into psychedelic drugs



More treatment types

Can support future potential indications and treatment types for patients.

Third party clinical trials

Can support clinical trials delivery required for new indications, supporting global drug development efforts; increasing clinic utilisation and adding a further revenue stream¹.

Emyria's psychedelic assisted therapy delivery playbook in action

Corporate Overview



ASX: EMD Trading Information

Last Traded Share Price **A\$0.044**

12-Month low / high A\$0.021 / 0.078

Shares Outstanding 806,483,233

Unlisted Options (including loyalty options) 310,147,902

Market Capitalisation ¹ **~A\$35m**

Last Cash Position ² ~A\$9m

Substantial Shareholder

Shareholder	%
#1 Holder: Greg Hutchinson, Exec. Chairman	5.29%


NOTES:
1. As of market close 24 July 2026
2. As reported in March 2026 Quarterly Report

Share Price, trading history



Shareholding

Top 50 ▶



Emyria | Summary



First mover advantage
globally

Significant **Total
Addressable Market**
AUS + globally

Generating **revenue**
Qtr on Qtr Growth

Capital Light approach
to clinics expansion

Delivering **durable**
outcomes

Developing the **P-AT**
playbook

Emyria (ASX:EMD) | Executing strongly

Delivering on commitments to shareholders



Recent Achievements

- 1st Private Health Insurer Funding treatments (Medibank)
- Opened 2nd Perth Empax Clinic
- Opened Brisbane Empax Clinic
- Opened Mornington (Victoria) Clinic
- 12 month PTSD Data Outcomes
- Commenced Empax Global Partnership Program (EGPP)
- Confirmed First Sydney Clinic
- 12 month TRD Data Outcomes

Future Drivers:

- 1st DVA approval
- Open Sydney Clinic
- Additional New Sites Confirmed
- 2nd Partner for Empax GPP
- New Funders Confirmed
- Potential Future Treatment Condition
- Leveraging scalable IP to create global partnerships

Emyria Board

Significant Clinical Services & Global Innovation Expertise



Greg Hutchinson
Executive Chairman

Health Service Leadership:

5D Clinics
Former CEO Sonic HealthPlus
leading 40+ clinics



Dr Michael Winlo
Executive Director

Research & Data Expertise:

Ex-Palantir healthcare lead,
Medical Doctor and Stanford MBA



Dr Karen Smith
Non-Executive Director

Biopharma Executive:

100+ clinical trials and 20+
regulatory approvals; Former Chief
Medical Officer and Global Head of
R&D at Jazz Pharma



Dr Mohit Kaushal
Non-Executive Director

Health IT Strategist:

Key role in Oak Street Health's
\$10.6B acquisition by CVS Health;
Served in Obama's Health IT task
force; Adjunct Professor at
Stanford



Prof Sir John Tooke
Non-Executive Director

Clinical Service & Health Payer Expertise:

Former President of the Academy of
Medical Sciences, influential roles at
BUPA and past advisor to Google
DeepMind



Contact Information



Greg Hutchinson

ghutchinson@emyria.com

**Mary-Ann
Rennie**

mrennie@emyria.com

**Investor /
Media Inquiries**

investors@emyria.com

emyria



**Visit Our
Investor Hub**